Netherlands-incorporated Mylan (Nasdaq: MYL) said it now needs just over 50% shares in hostile takeover target Perrigo (NYSE: PRGO) to control the company.
The generic drugmaker lowered the target number of shares from the initial 80% and said it will start the tender offer following its shareholder meet scheduled for end of August.
Drugmaker Perrigo’s chief executive Joseph Papa, said: "We don't believe Perrigo shareholders will tender into this transaction at any threshold and we are confident that there is no rational path to a full acquisition of Perrigo."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze